Physician profile
Arun Kumar
NPI 1639167372
$2,087.74
in general payments reported to CMS, 2019-2025
20 companies · $378 in 2025
The $378 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $70.55 · 2022: $287 · 2023: $464 · 2024: $399 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.03 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $521.05 | 2019-2025 | Xarelto, Spravato |
| Alk-Abello, INC | $264.72 | 2023-2025 | Odactra, Grastek |
| Novo Nordisk INC | $207.04 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $189.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $162.31 | 2019-2025 | Vaxneuvance, Gardasil 9, Proquad |
| Sanofi Pasteur INC. | $129.76 | 2019-2025 | |
| Exact Sciences Corporation | $117.49 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $64.25 | 2019-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $58.01 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.93 | 2022 | |
| Abbvie INC. | $47.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $44.08 | 2019-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $30.22 | 2023 | Gvoke Hypopen |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $28.28 | 2023-2024 | Doc Band |
| Agios Pharmaceuticals, INC. | $26.11 | 2025 | Pyrukynd |
| Aimmune Therapeutics, INC. | $20.82 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2023 | |
| Ironshore Pharmaceuticals INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.